Used in research and therapeutic development targeting inflammatory diseases, this antibody specifically inhibits Protease-Activated Receptor 2 (PAR2) signaling. It is applied in studies of chronic inflammation, pain, and autoimmune conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma. Due to its high specificity and neutralizing activity, it serves as a reference tool for validating PAR2-mediated pathways and evaluating drug candidates. It has also supported preclinical investigations into cancer progression where PAR2 activation contributes to tumor growth and metastasis. Its role as a benchmark reagent makes it valuable in comparative studies for antibody development and mechanism-of-action analyses.